EnClear Therapies Announces $10M Series A Financing
Summary
“Our differentiated technology has the potential to transform not only the treatment of this devastating disease, but also many other conditions related to the central nervous system.” EnClear also announced that Hillel Bachrach, Managing Partner at 20/20 HCP, Jason Camm, Managing Director and Chief Medical Officer at Thiel Capital, and Zafrira Avnur, Chief Scientific Officer and Partner at Quark Venture will join the Board of Directors effective immediately. “Hillel Bachrach, Jason Camm and Zafrira Avnur bring decades of experience and a deep understanding of the life sciences sector to our Board of Directors,” said Mr. DePasqua. We welcome Zafrira, Jason and Hillel to our Board of Directors and look forward to their contributions.” “The founders of EnClear are focused on producing a technology that could revolutionize the field by allowing fast diagnosis, delivery of any drug directly into the cerebrospinal fluid, and the development of new CNS-focused therapeutics,” said Jason Camm “I am excited to help EnClear grow their business to help the millions of patients living with CNS diseases.” “20/20 HCP was established to invest in life sciences companies with the potential to develop transformative new approaches for the treatment of disease,” said Hillel Bachrach. “We believe that EnClear’s technology has the potential to fundamentally change the way neurodegenerative diseases are treated and ultimately improve patients’ lives.” “Quark Venture supports and enables companies to grow, create value and be successful by providing not only financial support but also developmental, commercial and business development expertise,” said Karimah Es Sabar, CEO and Partner, Quark Venture. The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).